News|Articles|November 16, 2026

Tirzepatide cuts BMI 18.5% in adolescents with obesity

Fact checked by: Benjamin P. Saylor

Key Takeaways

  • Tirzepatide plus lifestyle intervention reduced BMI by 18.5% vs a 0.5% increase with placebo over 72 weeks in adolescents with obesity, and 54% of treated participants fell below the 95th percentile.
  • Gastrointestinal AEs affected 81.5% of tirzepatide recipients and peaked during dose escalation, and 9.3% stopped treatment because of AEs, so anticipatory counseling on tolerability matters.
SHOW MORE

In SURMOUNT-ADOLESCENTS, tirzepatide cut BMI 18.5% at 72 weeks vs a 0.5% rise with placebo in adolescents with obesity.

Once-weekly tirzepatide, added to a healthy lifestyle intervention, reduced body mass index (BMI) by 18.5% over 72 weeks in adolescents with obesity, compared with a 0.5% increase with placebo, according to results of the phase 3 SURMOUNT-ADOLESCENTS trial published in JAMA.¹ Nearly half of treated participants achieved a BMI reduction of at least 20%, and 54% no longer met the BMI threshold for obesity by study end.¹

The findings add tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, to the incretin-based therapies with substantial efficacy data in this age group. In an accompanying editorial, William J. Heerman, MD, MPH, of Vanderbilt Health, and colleagues wrote that the question is now "not whether pharmacotherapy has a role in pediatric obesity treatment," but which medication to use, and when.²

SURMOUNT-ADOLESCENTS trial design and tirzepatide efficacy in adolescents

The double-blind, placebo-controlled trial enrolled 160 adolescents aged 12 to younger than 18 years at 31 sites in Canada, the Czech Republic, Israel, Italy, Poland, and the US.¹ Participants had obesity (BMI ≥95th percentile) or overweight with at least 1 obesity-related complication; prepubertal adolescents were excluded.¹ After a 12-week lifestyle lead-in, participants were randomized 2:1 to tirzepatide escalated to a maximum tolerated dose of 5, 10, or 15 mg, or to placebo.¹ Mean age was 14.6 years, mean BMI was 38.6, and 61.9% were female.¹

The estimated treatment difference in percent BMI change was −19.0 percentage points (95% CI, −23.9 to −14.1; P < .001), and all 10 key secondary endpoints favored tirzepatide.¹ BMI reductions of at least 5%, 10%, 15%, and 20% were achieved by 79.6%, 71.4%, 63.4%, and 48.1% of tirzepatide recipients, respectively, vs 28.5%, 19.5%, 12.4%, and 7.9% of placebo recipients.¹ Body weight fell 16.9% with tirzepatide vs a 2.2% gain with placebo, and waist circumference decreased by 15.7 cm.¹ Physical comfort scores on the Impact of Weight on Quality of Life–Kids questionnaire also improved.¹ Blood pressure, triglycerides, high-density lipoprotein cholesterol, fasting insulin, and hemoglobin A1c moved in favorable directions, although these additional endpoints were not controlled for multiplicity.¹

Tirzepatide gastrointestinal adverse events and growth in adolescents

Adverse events (AEs) occurred in 95.4% of tirzepatide recipients and 82.4% of placebo recipients and were mostly mild to moderate.¹ Gastrointestinal events affected 81.5% of the tirzepatide group, led by vomiting (50.9%), nausea (50.0%), and diarrhea (45.4%), and clustered during dose escalation.¹ Ten tirzepatide-treated participants (9.3%) stopped treatment because of AEs, vs none receiving placebo; serious AEs occurred in 7.4% and 3.9%, respectively.¹

Depression or suicidal ideation was reported as an AE in 5 tirzepatide recipients (4.6%) and 1 placebo recipient (2.0%); none were serious, and all participants who reported ideation had a psychiatric history.¹ Height SD score and pubertal progression were similar between groups.¹

GLP-1–based pharmacotherapy for pediatric obesity in context

Obesity affects about 1 in 5 US adolescents.¹ The American Academy of Pediatrics clinical practice guideline recommends that pediatricians offer pharmacotherapy to adolescents 12 years and older with obesity as an adjunct to health behavior and lifestyle treatment.³ Orlistat, liraglutide, semaglutide, and phentermine-topiramate are FDA-approved for long-term obesity treatment in adolescents; tirzepatide is currently approved in pediatrics only for type 2 diabetes in patients 10 years and older.¹ In the STEP TEENS trial, semaglutide 2.4 mg reduced BMI by 16.1% at 68 weeks vs a 0.6% increase with placebo.⁴

Heerman and colleagues cautioned that because nearly all participants had obesity, most of it severe, the results support treating adolescents with obesity rather than overweight.² They also urged clinicians to individualize dosing rather than escalate reflexively to the maximum tolerated dose.²

Limitations of the SURMOUNT-ADOLESCENTS tirzepatide trial

Only 1 participant was overweight, and 1 had type 2 diabetes, and the cohort was 83% White and 97% non-Hispanic, limiting generalizability.¹ Most participants had reached Tanner stage 5, constraining conclusions about growth in earlier puberty.¹ Treatment discontinuation was higher with placebo (31.4%) than with tirzepatide (21.1%), driven largely by lack of efficacy.¹ Durability beyond 72 weeks and outcomes after stopping therapy remain unknown.² The trial was sponsored by Eli Lilly and Company, which manufactures tirzepatide.¹

References
1. Kelly AS, Pamidipati KC, Rachmiel M, et al. Tirzepatide in adolescents with obesity: the SURMOUNT-ADOLESCENTS randomized clinical trial. JAMA. Published online November 15, 2026. doi:10.1001/jama.2026.23420
2. Heerman WJ, Suarez L, Armstrong SC. Pediatric obesity pharmacotherapy: from therapeutic scarcity to therapeutic choice. JAMA. Published online November 15, 2026. doi:10.1001/jama.2026.22895
3. Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640. doi:10.1542/peds.2022-060640
4. Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245-2257. doi:10.1056/NEJMoa2208601

Related to this article